Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases
Articolo
Data di Pubblicazione:
2021
Abstract:
Objectives To compare the capacity of ibrutinib (IB) and idelalisib-rituximab (IDELA-R) of prolonging overall survival (OS) as in CLL patients, previously treated with chemotherapy only.
Tipologia CRIS:
01.01 Articolo in rivista
Keywords:
chronic lymphocytic leukemia; ibrutinib; idelalisib; therapy
Elenco autori:
Tripepi, GIOVANNI LUIGI; D'Arrigo, Graziella
Link alla scheda completa:
Pubblicato in: